The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...
PharmaTher Holdings Ltd. (the "Company” or "PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company requested a post-complete letter clarification ...
The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the ...
has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara® 1), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA 2 goal date ...
FDA sets PDUFA Action Date of June 28, 2025 ...
Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...
must submit an NDS within 12 months of filing a New Drug Application (NDA) in the US. This requirement is established by ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback